Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Chronic pain common in people living with HIV

HIVMA comprehensive guidelines recommend screening everyone with HIV, offering multidisciplinary treatment focusing on non-drug options.

Published
14 September 2017
From
EurekAlert
Is It Ethical to Take People Off HIV Meds for Cure Research?

Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.

Published
13 September 2017
From
Poz
New guidelines recommend that women avoid tenofovir & emtricitabine during pregnancy

Women should be offered the choice to avoid treatment with tenofovir and emtricitabine during pregnancy owing to a higher risk of stillbirth and early infant

Published
13 September 2017
By
Keith Alcorn
Alice Welbourn: WHO and the rights of women living with HIV

A recent set of articles on HIV in pregnancy, published by The BMJ and BMJ Open, raises concerns that some combination anti-retroviral therapies (cARTs) may harm babies. This highlights the need for changes to current WHO practice towards pregnant women living with HIV, which is no doubt well-intentioned but ill thought-out.

Published
12 September 2017
From
BMJ Opinion
New recommendations aim to help pregnant women with HIV make informed choices

New recommendations on antiretroviral drugs for pregnant women living with HIV can help women make more informed choices about benefits and harms, say a panel of international experts in The BMJ today. The panel recommend older drug combinations instead of the most widely used regimens to help reduce the risk of premature birth and neonatal death - which almost all women said they were extremely keen to avoid.

Published
12 September 2017
From
EurekAlert
HIV Survivors Give Their 'Last Gift' In A New San Diego Study

The Last Gift study at UC San Diego is a unique new research effort focusing on HIV patients with a terminal illness such as cancer, ALS or advanced heart disease. Participants must have a prognosis of less than six months to live. When they near the end of their lives, they stop taking their HIV medications and let researchers draw blood regularly to monitor the activity of the virus. They also consent to having their bodies autopsied within hours of death.

Published
11 September 2017
From
KPBS
Maraviroc matches boosted protease inhibitor treatment over 96 weeks

Treatment with maraviroc (Celsentri/Selzentry) is associated with durable HIV suppression and a favourable lipid profile, investigators report in HIV Medicine. The 96-week randomised study compared

Published
11 September 2017
By
Michael Carter
Who Resists Starting ART Therapy for HIV?

The study found that the demographic characteristics of patients who failed to initiate ART within 2 years of entering care were not as important as clinical factors. Higher CD4 count, lower viral load, and a prevalent AIDS diagnosis were clinical characteristics associated with delayed ART initiation.

Published
07 September 2017
From
MD Mag
Lipids improved by switching from ritonavir to cobicistat as a booster for darunavir

Switching from ritonavir to cobicistat is associated with significant improvements in cholesterol and triglyceride levels for people with dyslipidaemia, investigators from Spain report in HIV Medicine. Ritonavir was replaced

Published
06 September 2017
By
Michael Carter
Case reports of severe dolutegravir-related depression

Severe depression can be a side-effect of treatment with the anti-HIV drug dolutegravir. In HIV Medicine, clinicians from the Netherlands report two cases of rapid onset of

Published
05 September 2017
By
Michael Carter
← First12345...450Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.